Marpai Inc
OTCQX US:MRAI

  • LAST PRICE
    1.4400
  • TODAY'S CHANGE (%)
    -0.0500 (-3.3557%)
  • Bid / Lots
    1.3600/ 1
  • Ask / Lots
    1.7500/ 1
  • Open / Previous Close
    1.4225 / 1.4900
  • Day Range
    1.4000
    1.6500
  • 52 Week Range
    0.4000
    2.9650
  • Volume
    18,138

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 11, 2024

      Show headlines and story abstract

    • 4:07PM ET on Monday Nov 11, 2024 by MT Newswires
      Companies Mentioned: MRAI
      04:07 PM EST, 11/11/2024 (MT Newswires) -- ...

    • 4:05PM ET on Monday Nov 11, 2024 by PR Newswire
      Companies Mentioned: MRAI

      Turnaround continues to gain traction

      Marpai,Inc. ("Marpai" or the "Company") (OTCQX: MRAI),a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and is transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans, announced financial results for the third quarter of 2024. The Company expects to hold a webcast to discuss the results on November 12, 2024.

    • 4:05PM ET on Monday Nov 11, 2024 by Dow Jones
      Companies Mentioned: MRAI
      in operating activities (10,251) (15,324) ----------------------------- ------------------------------------- Cash flows from investing activities: Disposal of property and equipment -- 27 Net cash provided by (used in) investing activities -- 27 ----------------------------- ------------------------------------- Cash flows from financing activities: Proceeds from issuance of common stock in a public offering, net -- 6,432 Proceeds from sale of future cash receipts on accounts receivable 1,509 -- Proceeds from issuance of convertible debentures 5,978 -- Payments of convertible debenture issuance costs (499) -- Payments to buyer of receivables (1,816) -- Payments to seller for acquisition (631) -- Proceeds from issuance of common stock in a private offering, net 4,026 -- Net cash provided by financing activities 8,567 6,432 ----------------------------- ------------------------------------- Net decrease in cash, cash equivalents and restricted cash (1,684) (8,865) Cash, cash equivalents and restricted cash at beginning of period 13,492 23,117 ----------------------------- ------------------------------------- Cash, cash equivalents and restricted cash at end of period $ 11,808 $ 14,252 ============================= ===================================== Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet Cash and cash equivalents $ 830 $ 3,018 Restricted cash 10,978 11,234 ----------------------------- ------------------------------------- Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows $ 11,808 $ 14,252 ============================= ===================================== Supplemental disclosure of cash flow information Cash paid for interest $ 1,508 $ -- ============================= ===================================== Supplemental disclosure of non-cash activity Measurement period adjustment to Goodwill $ -- $ 198 ============================= =====================================

    • 4:05PM ET on Monday Nov 11, 2024 by Dow Jones
      Companies Mentioned: MRAI
      in operating activities (10,251) (15,324) ----------------------------- ------------------------------------- Cash flows from investing activities: Disposal of property and equipment -- 27 Net cash provided by (used in) investing activities -- 27 ----------------------------- ------------------------------------- Cash flows from financing activities: Proceeds from issuance of common stock in a public offering, net -- 6,432 Proceeds from sale of future cash receipts on accounts receivable 1,509 -- Proceeds from issuance of convertible debentures 5,978 -- Payments of convertible debenture issuance costs (499) -- Payments to buyer of receivables (1,816) -- Payments to seller for acquisition (631) -- Proceeds from issuance of common stock in a private offering, net 4,026 -- Net cash provided by financing activities 8,567 6,432 ----------------------------- ------------------------------------- Net decrease in cash, cash equivalents and restricted cash (1,684) (8,865) Cash, cash equivalents and restricted cash at beginning of period 13,492 23,117 ----------------------------- ------------------------------------- Cash, cash equivalents and restricted cash at end of period $ 11,808 $ 14,252 ============================= ===================================== Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet Cash and cash equivalents $ 830 $ 3,018 Restricted cash 10,978 11,234 ----------------------------- ------------------------------------- Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows $ 11,808 $ 14,252 ============================= ===================================== Supplemental disclosure of cash flow information Cash paid for interest $ 1,508 $ -- ============================= ===================================== Supplemental disclosure of non-cash activity Measurement period adjustment to Goodwill $ -- $ 198 ============================= =====================================

  • Nov 8, 2024

Peers Headlines